CWP
JAZZ icon

Concord Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Concord Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-79
Closed -$12K – 1304
2022
Q1 		$12K Buy
79
+7
+10% +$1.02K ﹤0.01% 739
2021
Q4 		$9K Buy
72
+65
+929% +$8.54K ﹤0.01% 807
2021
Q3 		$1K Sell
7
-58
-89% -$8.76K ﹤0.01% 845
2021
Q2 		$12K Sell
65
-41
-39% -$7.1K ﹤0.01% 596
2021
Q1 		$17K Buy
+106
New +$17.4K 0.01% 502

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Concord Wealth Partners's JAZZ Position: Q2 2022 in Review

Concord Wealth Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 79 shares — an estimated $12K sold.

Concord Wealth Partners first reported a position in JAZZ in Q1 2021 and held it in 5 quarters. The position peaked at $17K in Q1 2021. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

  • Concord Wealth Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Concord Wealth Partners sold 79 Jazz Pharmaceuticals shares in Q2 2022, an estimated $12K.
  • Concord Wealth Partners first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Concord Wealth Partners's Jazz Pharmaceuticals position peaked at $17K in Q1 2021.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Concord Wealth Partners's 13F filing for Q2 2022, filed 4 Aug 2022.